Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Cimerli Generic Name & Formulations
Legal Class
Rx
General Description
Ranibizumab-eqrn 6mg/mL (0.3mg), 10mg/mL (0.5mg); soln for oph intravitreal inj; preservative-free.
Pharmacological Class
Vascular endothelial growth factor (VEGF) inhibitor.
How Supplied
Single-dose vial (2mL)—1
Manufacturer
Generic Availability
NO
Cimerli Indications
Indications
Neovascular (wet) age-related macular degeneration (AMD). Macular edema following retinal vein occlusion (RVO). Diabetic macular edema (DME). Diabetic retinopathy (DR). Myopic choroidal neovascularization (mCNV).
Cimerli Dosage and Administration
Adult
Give by intravitreal inj. AMD: 0.5mg once a month (approx. 28 days); or 3 monthly doses followed by less frequent dosing (less effective); or 0.5mg every 3 months after 4 monthly doses (less effective). Monitor regularly. RVO: 0.5mg once a month (approx. 28 days). DME, DR: 0.3mg once a month (approx. 28 days). mCNV: 0.5mg once a month (approx. 28 days) for up to 3 months; may retreat if needed.
Children
Not established.
Cimerli Contraindications
Contraindications
Ocular or periocular infections.
Cimerli Boxed Warnings
Not Applicable
Cimerli Warnings/Precautions
Warnings/Precautions
Monitor intraocular pressure prior to and 30mins after inj. Monitor for perfusion of optic nerve and for infection following the inj (endophthalmitis and retinal detachments possible). Pregnancy. Nursing mothers.
Cimerli Pharmacokinetics
See Literature
Cimerli Interactions
Cimerli Adverse Reactions
Adverse Reactions
Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, intraocular inflammation; rare: arterial thromboembolic events, fatal events (with DME, DR); possible embryo-fetal toxicity.
Cimerli Clinical Trials
See Literature
Cimerli Note
Not Applicable
Cimerli Patient Counseling
See Literature
